The Danish eye-screening software
manufacturer, RetinaLyze System A/S (Ltd.), a market leader in retinal
screening software, is introducing another new and accessible eye-screening
service; an artificial intelligence-based screening service designed to detect glaucoma called
“This new service will revolutionise how eye-screening for glaucoma
is performed and also change who can perform them. We are, and always have
been, committed to make eye-screenings
accessible for the general public and providing our customers with easy,
efficient and fast solutions for performing eye-screening for eye-diseases,”
says Ganesh Ram, CCO of RetinaLyze System A/S (Ltd.).
Glaucoma is the leading cause of irreversible
blindness in the world. In 2013, the number of people with glaucoma worldwide
was estimated to be 64,3 million, increasing 76 million in 2020 and to 111,8
million in 2040.
While there are no known cures
for glaucoma, blindness or significant vision loss from glaucoma can be
prevented if the disease is recognized in the early stages. In its most
prevalent form—primary open angle
glaucoma—vision loss is silent, slow, and progressive. It typically affects
side vision first (peripheral vision) and as it progresses, central vision is
Currently, regular eye exams are
the best form of prevention against significant glaucoma damage. The earlier
the condition is discovered, the easier and cheaper it is to stop the disease
RetinaLyze System aims to make
eye-screenings accessible for the general public. To make this happen,
RetinaLyze System’s services lower the cost of each screening and reduce the
price and complexity of the equipment necessary to perform eye-screenings. The new
RetinaLyze Glaucoma algorithm furthermore makes it possible for
eye-specialists, such as ophthalmologists, optometrists and nurses, to perform
glaucoma screenings efficiently and safely. RetinaLyze Glaucoma analyzes retinal images automatically.
It can assess the risk of having glaucoma and gives a result instantly. The
entire process involves only the image from fundus cameras – no visual field
analyzer or tonometer is necessary.
RetinaLyze Glaucoma assesses
the level of hemoglobin in
the Optic Disc, which can be used as a
measurement of damage to the Optic Nerve Head, and calculates the risk of having signs of Glaucoma. The algorithm uses only fundus images as input, but achieves similar performance as visual perimetry and OCT screening methods.
RetinaLyze Glaucoma is a new algorithm, which
is a part of the RetinaLyze web application.
The RetinaLyze web application offers easy-to-use automated analysis of retinal
images for signs of Diabetic Retinopathy, AMD and Glaucoma as well as a built-in
The ease-of-use, as well as the
simplicity of the eye exam and the speed of the result, makes the RetinaLyze
service an ideal eye-screening tool for clinics and optometry practices of all
RetinaLyze System will begin
delivering the RetinaLyze Glaucoma service to customers on the 1st of May 2018. More information will follow in the coming days and weeks.
RetinaLyze System A/S is a medical
technology company established in 2013, which is represented in 35 countries
all over the world. The company delivers groundbreaking decision support
tools to eye-screening professionals to enable efficient, accessible and fast
eye-screenings. All our algorithms and services are CE-marked, clinically
validated and patented.
Chief Commercial Officer
Tel. +45 25 94 44 08
Tel. +45 42 70 12 03